


2nd MULTIDISCIPLINARY MEETING TO DISCUSS GAPS . . IN BLADDER . . CANCER

BARCELONA 10–11 . JULY . 2025



REGISTRATION

<https://eira.meetingpharma.com/courses/iimeetingbladder25>

AGENDA

SCIENTIFIC COORDINATORS

Dr. Pablo Maroto

Department of Medical Oncology

Hospital de la Santa Creu i Sant Pau. Barcelona, Spain

Dr. Óscar Rodríguez Faba

Faculty member Uro-oncology unit and Kidney transplant division

Fundació Puigvert. Barcelona, Spain

SCIENTIFIC ORGANIZATION



ENDORSED BY



15.45–16.00

PRESENTATION

16.00–16.30

**BLOCK I.
ROLE OF THE PATHOLOGISTS**

Moderator

Dr. Ferran Algaba

POLL WITH THE AUDIENCE

CONTROVERSIES

- What molecular classification should be used? What the pathologist can and should tell us about a urothelial tumor and variant histologies?
Dr. Ferran Algaba
- Biomarkers in bladder cancer. What information do we need from the pathologist? How to describe PDL1 and other molecular biomarkers? Are they useful in present clinical practice?
Dra. Nuria Juanpere

Q/A

16.30–18.00

**BLOCK II.
NON-MUSCLE INVASIVE BLADDER
CANCER (NMIBC)**

Moderator

Dr. Joan PalouNON-MUSCLE INVASIVE BLADDER CANCER,
GOOD AND INTERMEDIATE PROGNOSIS

POLL WITH THE AUDIENCE

- Current role of white light enhanced technologies for NMIBC detection and treatment.
Dr. Mario Alvarez-Maestro
- Emerging role of urinary markers for NMIBC bladder detection and follow-up.
Dr. Fernando Lozano

Update about clinical trials in progress for intermediate risk NMIBC.
Dr. Andrea Gallioli

Discussion and description of current guidelines.
Dr. Fernando Lozano

Q/A

HIGH RISK NMIBC

Current evidence updates and guidelines.

Dr. Angelo Territo

- BCG naive: Update on clinical trials.
BCG unresponsive: Endovesical approach (TAR) vs systemic treatment (Checkpoint inhibitors).
Dr. Oscar Rodriguez Faba
- Neither TAR nor Checkpoint Inhibitors.
Dr. Fred Witjes
- Definition of patients candidates to early cystectomy.
Dr. Evangelos Xylinas

Q/A

18.00–18.30

COFFEE BREAK

18.30–19.00

Moderator

**BLOCK III.
BARRIERS AMONG SPECIALTIES. PATIENT
FLOW AND HOW TO INCORPORATE
PATIENTS INTO CLINICAL DECISIONS**

Dr. Francesco Sanguedolce

DISCUSSION

- Defining the multidisciplinary team and Multidisciplinary meetings.
Objectives of a multidisciplinary meeting.
Dr. Bertrand Tombal
- Patient Flow and patient journey along bladder cancer.
Dr. Óscar Buisan
- Modern ERAS protocols for Radical Cystectomy
Dra. Silvia Castellarnau

ROUND TABLE

19.00–19.30

MEET THE EXPERT

Unmet medical needs and lines of research in prostate cancer

Dr. Bertrand Tombal

Presented by **Dr. Francesco Sanguedolce**
& **Dr. Óscar Buisan**

9.00–9.30

POLL WITH THE AUDIENCE

9.30–11.00

**BLOCK IV.
MUSCLE INVASIVE BLADDER CANCER
(MIBC)**

Moderator

Dr. Alberto Breda**BLADDER PRESERVATION****DISCUSSION**

How to evaluate local response in bladder cancer

- Radiology point of view.
Dr. Richard Mast
- Role of ctDNA.
Dr. Andrea Necchi
- Role of Immunotherapy and new trials.
NIAGARA. Do we have a new standard of care?
Dr. A. Pinto
- MIBC with CR after NAC: where do radical cystectomy and lymphadenectomy stand today and role of robotics.
Dra. M^a José Ribal

MEET THE EXPERT

Is Bladder Preservation Feasible Without radiotherapy?

Introduction: **Dr. Andrea Necchi**Discussion by **Dr. J. Puente & Dr. Breda**

11.00–11.30

COFFEE BREAK

11.30–12.25

Moderator

METASTATIC DISEASE**Dr. A. Pinto****POLL FOR THE AUDIENCE**

- New guidelines in the management of bladder cancer.
Dr. Miguel Ángel Climent
- Still a role for chemotherapy in the future? Maintenance or triplet therapy?
Dr. A. Gómez de Liaño
- Biomarkers of response to therapy.
Dra. G. Anguera
- Discussion.

12.25–13.15

MEET THE EXPERT

Unmet medical needs and lines of research in kidney cancer

Dr. Ferran Algaba & Dr. Óscar Rodríguez Faba

Presented by Dr. A. Gómez de Liaño

Q/A

13.15–13.45

VIDEO SESSION

Tips and tricks for robotic cystectomy and urinary diversion

Dr. JM. Gaya

13.45

FINAL CONCLUSIONS


Dr. Óscar Rodríguez Faba & Dr. Pablo Maroto

- Dr. Ferran Algaba Fundació Puigvert (BCN)
- Dr. Mario Alvarez-Maestro Hospital La Paz (Madrid)
- Dra. G. Anguera Hospital Sant Pau (BCN)
- Dr. Alberto Breda Fundació Puigvert (BCN)
- Dr. Óscar Buisan Hospital Bellvitge (BCN)
- Dra. Silvia Castellarnau Fundació Puigvert (BCN)
- Dr. Miguel Ángel Climent IVO (Valencia)
- Dr. Andrea Gallioli Fundació Puigvert (BCN)
- Dr. JM. Gaya Fundació Puigvert (BCN)
- Dr. A. Gómez de Liaño CHU Insular Materno-infantil (Las Palmas)
- Dra. Nuria Juanpere Hospital del Mar
- Dr. Fernando Lozano Hospital Vall d'Hebron (BCN)
- Dr. Richard Mast Hospital Vall d'Hebron (BCN)
- Dr. Andrea Necchi Hospital San Raffaele (Milano)
- Dr. Joan Palou Fundació Puigvert (BCN)
- Dr. A. Pinto Hospital La Paz (Madrid)
- Dr. J. Puente Hospital Clínico San Carlos (Madrid)
- Dra. M^a José Ribal Hospital Clínic (BCN)
- Dr. Óscar Rodríguez Faba Fundació Puigvert (BCN)
- Dr. Francesco Sanguedolce Fundació Puigvert (BCN)
- Dr. Angelo Territo Fundació Puigvert (BCN)
- Dr. Bertrand Tombal Université Catholique de Louvain (UCL)
- Dr. Fred Witjes Oncological urologist
- Dr. Evangelos Xylinas Bichat Claude Bernard Hospital Assistance Publique, Hôpitaux de Paris, Paris Cité University

VENUE

RECINTO MODERNISTA
HOSPITAL SANT PAU

C/ de St. Antoni Maria Claret, 167
08025 Barcelona



SPONSORS

NOTES

[illegible]

CONTACT

MeetingPharma

A/A Fernando Ochoa Lainez
fochoa@meetingpharma.com
www.meetingpharma.com

